


Quality of Life

Helsinn Group
Sustainability Report
2021



Published in 2022

HELSINN
Building quality cancer care together

Table of Contents

LETTER FROM OUR LEADERSHIP	4
ABOUT THIS REPORT	6
OUR COMPANY	8
History & Milestones.....	10
Our Vision, Mission & Values.....	14
Our Business Model.....	16
SUSTAINABILITY AT HELSINN	18
Material Topics: What Matters Most.....	20
QUALITY OF LIFE FOR OUR PATIENTS.....	24
Our Products	25
Our Science.....	26
Our Partnerships.....	27
QUALITY OF LIFE FOR OUR PEOPLE	34
Job Satisfaction, Motivation, Retention.....	36
Training.....	37
Safety, Health & Wellness.....	38
QUALITY OF LIFE IN OUR COMMUNITIES	40
QUALITY OF LIFE IN OUR ENVIRONMENT	42
Energy	43
Water	44
Industrial Waste.....	45
Paper	46
CO2e Emissions	48
ACTING RESPONSIBLY	54
The Compliance Program	54
The Helsinn Code of Conduct	55
The Helsinn Compliance and Quality Manual	55
Compliance Policies and Procedures.....	55
Quality	56
Data Protection and Privacy	57
Corporate Governance	58
ECONOMIC VALUE CREATION.....	62
Financial Highlights.....	62
HELSINN AND THE SDGS	64
ACRONYMS LIST	66

Letter From Our Leadership

Dear Stakeholders,

2021 was a transitional year for Helsinn, a year that marked the beginning of a new era for our company. Two significant events marked this year. First, the spin-off of the API chemical factory and other minor businesses, now part of 3B Future, the Family holding, in order to focus Helsinn in the oncology and rare disease sectors. Second, Helsinn achieved the Carbon Neutral certification for the second year.

In a world that is increasingly volatile, uncertain, complex, and ambiguous, we need to change quickly, adapt to the new normal, be extremely flexible and transparent.

The progress we made in 2021 puts Helsinn on the right path to continue our Mission and increase our readiness for the future. Being successful and operating sustainably is how we generate impact for our stakeholders and deliver on our Mission.

We are totally committed to running a responsible and sustainable business, to delivering superior products, to reducing and improving our impact on the environment and society. Sustainability has always been one of the main drivers in our corporate culture and has become a crucial element of our strategic vision.

We have consistently improved our operations in the past years and made them more environmentally friendly. Our goal is to have the least negative impact possible that a company such as ours can have on the planet and the very people we are trying to help.

In 2021 we achieved a landmark: after years of reduction in our carbon footprint, we become a Certified Carbon Neutral Company, through the purchase of high quality, Gold Standard

certified credits from project with a direct impact on the lives of rural communities in Ethiopia and Madagascar. Achieving carbon neutrality follows a rigorous and continued focus on the Group's environmental performance, addresses 100% of Scope 1, 2 and 3 and represents a key milestone in Helsinn's sustainability journey. As we often say, we are all in this together.

At Helsinn we are deeply convinced that Sustainability is not a goal but a never-ending journey. We can always do better, and we are fully committed at all levels to constantly improve and deliver on our promises. Helsinn is proud of leading an extraordinary team of committed professionals, and we want to thank all our people for all we have achieved in 2021.

Yours truly,

Riccardo Braglia

Executive Chairman



Giorgio Calderari

Group CEO



About this Report

Quality of Life 2021 is our sixth Group Sustainability Report, it covers our worldwide operations for 2021 with reference to previous periods. Its objective is to present to our stakeholders our sustainability and ESG performance, our commitments and our goals.

The report contains the quantitative and qualitative information necessary to understand Helsinn's material aspects. The Framework "Quality of Life" is since 2014 at the base of our sustainability strategy and represents our commitment towards becoming more sustainable every day as we strive to fulfill our mission.

Our material aspects have the potential to have a major financial and non-financial impact on our business. As a result, they are the most important factors that can impact our stakeholders' opinions or decisions about Helsinn and its activities.

We have chosen not to have this report externally assured, as most of the material information reported has either already been verified by third parties or complies with the most stringent criteria of each country of operation.

In 2015 the United Nations adopted 17 new Sustainable Development Goals ('SDGs') which contain 169 associated targets integrating the economic, social and environmental components of sustainable development. Helsinn actively supports the SDGs, specifically Goals 3, 4, 6, 10, 11, 12, 13, 16, 17, where we can give our direct contribution, and we encourage our partners and stakeholders to integrate them in their strategy and operations.

This report is published under the coordination of Manuela Pedretti, Head of Group Top Management Office Manager and Project Leader, with the support of Positive Organizations, Lugano, Switzerland.

We would like to thank all our employees who have provided their precious contribution for this report.

Phone: +41 (0) 91 985 2121

Mail: **sustainability@helsinn.com**

Publishing a Group
Sustainability
Report according
to GRI Frameworks
since 2015



Our Company

Helsinn is a global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world, with a leading position in cancer supportive care.

A third-generation, family-owned company, since 1976 Helsinn focuses on improving the lives of patients, guided by core values of respect, integrity and quality.

It operates a unique licensing business model with integrated drug development and manufacturing capabilities and has a fully integrated supply chain and product development through its subsidiary in Ireland.

It has a commercial presence in 190 countries either directly, with operating subsidiaries in the U.S. and China, or via its network of long-standing trusted partners.

Every business unit of our Group operates as a separate legal entity.

• Helsinn Healthcare SA — HHC

The Group's global **Headquarters** in Lugano, Switzerland, oversees all central functions: Group general management, human resources, administration & finance, legal affairs, compliance, quality, data protection, clinical and research development, manufacturing & CMC, pharmacovigilance and regulatory affairs, medical affairs, commercial operations and business development operations, marketing, market access, information and communication technology, corporate communication.

• Helsinn Birex Pharmaceuticals Ltd. — HBP

At our integrated GMP facilities in Dublin, Ireland, we develop and manufacture our **finished dosage products** and coordinate the global logistics.

- **Helsinn Therapeutics (US), Inc. — HTU**

HTU, our subsidiary in Iselin, NJ, USA, manages a **commercial and medical organization in the US**, with a portfolio of oncology products

- **Helsinn Pharmaceutical (Beijing) Co. Ltd., P.R.C. — HPC**

Our Beijing office coordinates **clinical and regulatory activities** for new product registration with NMPA, collaborates with and provides support to our partners on the commercialization of our products, including **co-detailing** in Shanghai, where we have established a branch in 2017.

Helsinn Birex
Pharmaceuticals Ltd.
Dublin, Ireland



Helsinn Pharmaceuticals (Beijing) Co., Ltd.
Beijing, PRC
Shanghai (branch), PRC



Helsinn Therapeutics (US) Inc.
Iselin NJ, US



Helsinn Healthcare SA
Lugano, Switzerland

History & Milestones



• **1976**

- **Helsinn** is established by the Braglia family in Ticino, Switzerland

• **1980**

- Worldwide licensing agreement is signed with 3M Pharmaceuticals for nimesulide, a leading non-steroidal anti-inflammatory drug (NSAID)

• **1984**

- **Helsinn Chemicals SA**, the

Group's first manufacturing plant opens in Biasca, Switzerland

• **1985**

- Nimesulide is launched on the international market

• **1990**

- Acquisition of an Irish pharmaceutical company, now **Helsinn Birex Pharmaceuticals Ltd** (HBP), in Dublin

• **1995**

- Relocation of HBP

to new premises in Damastown

• **1998**

- Worldwide licensing agreement is signed with Syntex-Roche for palonosetron, a 5-HT₃ antagonist used in the prevention and treatment of Chemotherapy-Induced Nausea and Vomiting (CINV) and Post-Operative Nausea and Vomiting (PONV)

• **1999**

- **Helsinn Advanced Synthesis SA**, the second Swiss manufacturing plant, is inaugurated in Biasca, dedicated to highly potent active pharmaceutical ingredients (HPAPIs)

• **2003**

- Palonosetron is launched in the US by our partner MGI Pharma, now Eisai Inc.

•2005

- Palonosetron is launched in EU and in Latin America
- Netupitant is in-licensed from Roche with global rights for development and commercialization

•2009

- The US biotech company Sapphire Therapeutics Inc. is acquired: creation of **Helsinn Therapeutics (US) Inc.** (HTU). The operation includes the rights

for a ghrelin-based development platform and anamorelin, a novel therapy in development for the management of cachexia-related symptoms in cancer patients

•2010

- Helsinn Chemicals SA, and Helsinn Advanced Synthesis SA, Biasca, Switzerland merger. The manufacturing facility is from now on called **Helsinn Advanced Synthesis SA**

(HAS)

- A new R&D center of excellence opens at HBP

- Palonosetron is launched in Japan

•2011

- New analytical laboratories open at HBP

- Our CEO Riccardo Braglia receives the prestigious "2011 Entrepreneur in Italian-Speaking Switzerland" award

•2012

- Ernst & Young

recognizes Riccardo Braglia as the "Best Entrepreneur in the High Tech/Life Sciences category in Switzerland" and selects him to represent Switzerland at The Worldwide Entrepreneur of the Year contest in Montecarlo

- Helsinn opens a representative office in Beijing in China and files for an IND application for netupitant/palonosetron fixed-dose-combination

- Helsinn opens a new chemical plant

for the production of anticancer compounds at HAS

•2013

- Helsinn establishes a new commercial organization within its subsidiary HTU in order to conduct direct sales and marketing activities within the US market

•2014

- The US Food and Drug Administration (FDA) approves netupitant/palonosetron fixed-

dose-combination for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV). It is launched in the US in the co-selling partnership between HTU and Eisai

•2015

- The European Medicines Agency (EMA) approves netupitant/palonosetron fixed-dose combination oral. The product has been launched in several European Countries,



in Switzerland and in Australia

- Start of clinical trials for I.V. formulation netupitant/palonosetron fixed-dose-combination

- Helsinn obtains the Global CEO Cancer Gold Standard Accreditation, which recognizes our commitment to reducing cancer risk through the promotion of a healthier lifestyle, earlier disease detection and high quality care in the workplace

- HTU moves into the new offices, located in a LEED Gold building

in Iselin, NJ

- The First Helsinn Group Sustainability Report ("Quality of Life") is published

• 2016

- Helsinn obtains exclusive rights to promote and sells netupitant/palonosetron fixed-dose combination in the US, previously co-detailed with Eisai

- Helsinn signs an agreement with MEI Pharma, Inc. an oncology company focused on the clinical development

of novel therapies for cancer, to enter into an exclusive licensing, development and commercialization contract for pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukaemia (AML) and other potential indications

- Opening of **Helsinn International Services (HIS)** and launch of **Helsinn Investment Fund (HIF)** which is focused on early-stage investments in areas of high unmet

patient need

• 2017

- Helsinn Launches "Helsinn Cares" Patient Support Services in the US, a Patient Assistance Program and Voucher Program to support both insured and uninsured patients

- Helsinn starts a collaboration with Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease

- On the roof of HBP in Dublin a new PhotoVoltaic electricity generator is installed. 200 panels capture solar power and generate up to 50KW/day

- The First Conquer Cancer Foundation/ Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, is awarded

- The Shanghai Branch of Helsinn Pharmaceuticals (Beijing) Co. Ltd., opened in August

• 2018

- Acquisition of

mechlorethamine/chlormethine for MF-CTC treatment from Actelion, marking Helsinn's first step into the cancer therapeutics field

• 2019

- Our CEO, Riccardo Braglia, joins the Board of the Conquer Cancer Foundation
- Helsinn Advanced Synthesis (Biasca) unveils its new anticancer ingredients plant and drastically reduces emissions

by shifting from heating oil to renewable energy by latching on to the district heating plant system of Nuova Energia Ticino (NET)

- Creation of a new unified Group Compliance & Quality Division
- Global CEO Cancer Gold Standard: once again Helsinn was part of the accredited Companies, recognized for a variety of wellbeing related activities with the commitment of reducing the risk of

cancer amongst our employees

2020

- Helsinn: Distant but Close section on corporate website during COVID-19 crisis
- Introduction of Smart working policies and safety protocol groupwide, 70% of staff working from home
- Helsinn receives Swiss Biotech Success Stories Award 2020
- netupitant/ palonosetron fixed-dose combination I.V. approved in EU, and the liquid formulation

is approved and launched in US, while the oral formulation is launched also in China

- Opening of new AntiCancer production unit in HAS for the development, analysis, and manufacturing of anti-cancer APIs.
- Introduction of Early Access Program (EAP) Online Portal
- Accreditation PRO FAMILIA Switzerland «Company Family Friendly Award» 2020

2021

- Approval and launch of anamorelin in

Japan by ONO Pharmaceuticals

- Divestment of the Integrative Care franchise completed refocus on oncology
- Spin off of HAS Advanced Synthesis, the chemical factory in Biasca, and of 3B Future Health Ventures, the Monaco-Based advisory services company, as independent entities from Helsinn and now part of the Braglia family holding, 3B Future
- Carbon Neutral company certification achievement



Helsinn

Carbon Neutral
2021

www.climate-services.ch

according to ISO 14064



Our Vision, Mission & Values

Quality

Maintaining the highest standards means we produce world-class solutions aimed at improving the quality of life for people with cancer

Integrity

Being honest, ethical and trustworthy is helping us become the cancer care partner of choice

Respect

Treating our partners as we would like to be treated leads to strong, enduring relationships

Mission

To bring better todays to even more people through a portfolio of quality innovative oncology assets, guided by solid values of respect, integrity and quality. We are committed to making everything we do count towards the best therapies and supportive care for cancer patients, from the products we license to the rigorous standards we apply as a pharmaceutical manufacturer. At Helsinn we are committed to extending the reach of our quality care and use our expertise to fulfil more unmet needs and build better todays for more patients worldwide.

Vision

To transform Helsinn into a leading oncology company driven by our focus on extending and improving the lives of people with cancer all over the world.

Values

We are a family-run company, and have retained our founding values of quality, integrity and respect, which guide everything we do.

Our three core values
are supported by our
commitment to Creativity,
Team Alignment,
Diversity and Inclusion
and Resourcefulness



Our Business Model

During the recent years, the company entered in a transformational phase in order to build innovative cancer and rare disease therapies.

At the base of our business model and of Helsinn's development over the course of 40 years is the in- and out-licensing of pharmaceutical molecules: the first step of the process is to identify innovative early-to-late-stage new chemical entities from third parties. After completing their development by performing pre-clinical and clinical studies, supported by chemistry, manufacturing and control development, we then submit an application for worldwide market approval.

Thanks to this model we have built a network of partners that we assist and support by providing products and scientific management services (i.e. commercial, regulatory, financial, legal support, medical education and market access), while centrally managing the drug safety and pharmacovigilance of our products. The synergy of integrated early and late-stage licensing programs together with our internal R&D creates a comprehensive portfolio of effective pharmaceuticals and specialized therapies. Helsinn out-licenses its products to commercial partners in its global distribution network while promoting and distributing to the cancer-care community in the US through our subsidiary Helsinn Therapeutics.

We are a global company: our production facilities are located in Dublin, Ireland. Our products are manufactured according to the highest quality, safety and environmental standards, in compliance with the US Food and Drug Administration (FDA), EU European Medicines Agency (EMA), Swissmedic, Japanese PMDA, other local Authority agencies, and Pharmaceutical Inspection Convention (PIC).

In the US we market our portfolio through our local subsidiary, creating added value thanks to the direct relationship with healthcare professionals. This B2B – B2C model allows us to effectively reach healthcare professionals and most importantly, a greater number of patients.

In China we have a local subsidiary with offices in Beijing and Shanghai, who coordinates clinical and regulatory activities for new product registration with CFDA, collaborates with and provides support to our partners on the commercialization of our products.

Business model



Sustainability at Helsinn

We know that long-term success is built in partnership with the communities we live and work in; from the environment and the people who work at Helsinn, to the doctors and patients that use our products, we're proud to take our commitments seriously.

Sustainability is a journey, and we are fully committed at all levels to engage in it.

We believe it is the only approach possible towards creating long-term value by taking into consideration how we operate in the ecological, social and economic environment. Our sustainability plan is aligned with our strategy and embedded in our culture.

This commitment was never so important as during the past two years, beset by the COVID pandemic. The challenges we all faced were enormous and totally unexpected. They highlighted the important role of the pharmaceutical industry, and reminded us of our great responsibility to patients, collaborators, healthcare professionals, the communities in which we work and live and the planet.

In 2020 we had to adapt, quickly and drastically. In 2021 we had to continue performing activities despite the high level of uncertainty; during these two years, an enormous effort was required from each and every one of us.

We have come a long way since we took our first steps and published the Sustainability Report for one of our subsidiaries in 2012. We are certainly proud of our progress but in order to face the new normal we need to challenge ourselves and commit to constant improvement.

One of our main objectives remain making our products accessible to as many patients as possible. To accomplish this, we work with our partners in nearly one hundred markets, taking all needed measures to make our products available even when the sales volumes do not cover the investments. We want to pursue these goals while at the same time minimizing our environmental footprint. From 2021 we are a Carbon Neutral company: it's an important milestone and we are committed to continue on the path towards a zero-carbon economy.

Our co-workers and our associates are fundamental in making this a reality. We often hear they feel like they are part of a family: considering that Helsinn is a family business, this makes us incredibly proud. Taking excellent care of our team members, having patients' best interests at heart, building long-term, trust-based interactions with business partners, and playing an active role in our community are all crucial to creating long-term relationships which are key to ensuring the company's success.

Our Stakeholders

We have a clear commitment to doing business with integrity. In everything we do, we aim to be transparent and honest with our stakeholders.

Our global stakeholder network consists of the people our operations impact and those who influence our activities.

They play an essential role in our business and we take into consideration their view and outlook at every step. We are proud of the relationships we have built over the years and we continue to listen to their suggestions and their concerns.

We firmly think that our unique value proposition goes beyond the capabilities and therapies we offer: above all it's about the quality of our interactions.

We welcome all possibilities for cooperation that can create shared value. As for the previous reports, we analyzed in detail the approaches and procedures that we use to interact and cooperate with our different stakeholder groups.

How we engage

PATIENTS, THEIR FAMILIES, PATIENTS' ASSOCIATIONS	Corporate website, product websites, support for disease awareness websites and campaign, non-promotional activities, support of patient association initiatives, sponsoring congresses and other educational activities, educational and research grants, periodical & ad-hoc meetings, Early Access Programs.
EMPLOYEES	Biannual CEO presentations, Helsinn News, ongoing communication via corporate intranet, company events, Code of Conduct, staff town hall meetings, R&D retreats, training programs, project/product management meetings, Helsinn Academy, Quality, Safety, Integrity Portal, etc.
HEALTHCARE PROFESSIONALS	Advisory Board meetings, speakers' programs, data presentation at congresses, publications in peer reviewed journals, meetings related to clinical trials, meetings with clinical experts, product websites, Integrity Portal.
SHAREHOLDERS & BOARD	Periodical reporting on business progress, annual meeting.
BUSINESS PARTNERS	Regular meetings, congresses & exhibitions, InTouch knowledge sharing platform, constant interactions with commercial division, annual distributors' meeting, educational incentive trips for sales force, scientific trainings, support of local events, Integrity Portal.
SUPPLIERS	Partner selection meetings, audits, quality assurance inspections, business terms discussion, Third Party Codes of Conduct.
GOVERNMENT, REGULATORS & PAYERS	Meetings and ongoing dialogues with regulatory authorities, environmental health and safety reports.
TRADE & INDUSTRY ASSOCIATIONS	Periodical meetings, Helsinn representatives on committees and boards, industry trade shows.
LOCAL COMMUNITIES, PHILANTHROPIC INSTITUTIONS	Scholarships, schools visits at our plants, sponsoring of cultural activities, sponsorship of educational institutions in Africa, contribution to charities and local community services, hiring and training of apprentices.

Material Topics: What Matters Most

The 6 Material Areas in our time-tested Sustainability framework provide the basis of our analysis: they focus on the environmental and social and impacts of our activities through the whole value chain, and on the governance practices that lead to effective decision making and responsible practices. By asking ourselves which opportunities and threats are most relevant to our business in each of these areas, we are able to focus on our Material Aspects, on what matters most now and in the future.

In 2020, we reviewed our materiality assessment with the participation of all senior executives. For this report, we are maintaining the same framework as there are no compelling reasons to update our materiality assessment for 2021.

The material topics and their relevance are assessed in terms of:

- their priority, both in connection to business strategy and importance for the main stakeholders
- how we, and our stakeholders, can control or influence these topics
- their potential to have a direct or indirect impact on an organization's ability to create, preserve or erode economic, environmental, and social value.









































Within the 6 areas, we re-examined the importance of the topics which were considered material during the assessment carried out in the previous years, as well as other topics. We took into consideration the GRI Standards, the SASB biotech and pharma standards, the SDGs, research briefs on the Pharma, Biotech and Chemical sectors, as well as the analysis of our peers.

The topics that ranked the highest are: Culture of Excellence, Emissions, Supply Chain Transparency & Monitoring of Suppliers, Diversity & Equal opportunities, Constant Learning, Health outcome contribution & cost optimization, Commitment to Education, Innovation and R&D pipeline.






Topics & Boundary of Impacts

	Internal impact	External impact
Quality of Life for Our Patients		
Access to medicines		
Disease awareness, patients' education and assistance		
Safety of clinical trials		
Health outcome contribution & cost optimization		
Quality of Life for Our People		
Safety health & wellness		
Job satisfaction, motivation & retention		
Compensation & benefits		
Constant learning		
Diversity & equal opportunities		
Culture of excellence		
Quality of Life in Our Communities		
Local communities		
Philanthropic contributions		
Volunteer activities		
Commitment to education		
Quality of Life in Our Environment		
Water		
Energy		
Waste & effluents		
Emissions		
Acting Responsibly		
Standards & code of conduct		
Stakeholders' engagement & external communication		
Manufacturing & operational excellence		
Supply chain transparency & monitoring of suppliers		
Economic Value Creation		
Long-term economic performance		
Value added & redistributed		
Spending on local suppliers		
Innovation and R&D pipeline		

This matrix highlights the areas of importance for our sustainability performance and at the same time sets the base upon which we will be amending our sustainability strategy.



Quality of Life for Our Patients

Our journey in cancer care started in 1998 when we signed a licensing agreement with Syntex-Roche for palonosetron, a drug used in the prevention and treatment of CINV.

Today, we are a global biopharma company. Our comprehensive portfolio of cancer supportive care products for patients undergoing treatment for cancer, chemotherapy-induced nausea and vomiting and dermo-is available around the world.

We work with a group of longstanding, worldwide partners who share our vision and values, with a unique business model combining integrated early- and late-stage licensing programs to complement our own drug discovery and development.

Our commitment to the quality of life of our patients has remained constant throughout the years and it is at the forefront of our activity. While the prevalence of cancer continues to grow, significant advances have been made in cancer care: today, even if a full recovery is not always possible, many cancers can be managed thanks to advanced therapies. Indeed, the National Comprehensive Cancer Network (NCCN) believes that physicians and practitioners now consider certain types of cancers a chronic condition.

There is an increased focus on the relative cost-effectiveness and sustainability of delivering high-quality cancer care, and we are committed to developing highly efficient therapies.



Over the past five years,
26 clinical trials sponsored
(including 11 Phase 3 studies),
involving more than **3'000**
subjects across approximately
900 clinical centers

14 formulations
developed covering
different oral and
injectable dosage
forms

Our Products

Cancer Supportive Care

We are convinced that every day is precious, perhaps even more so for people living with cancer. Unfortunately, the side effects of treatments, such as chemotherapy-induced nausea and vomiting, mucositis and dermatitis, can adversely affect the quality of their daily lives. We're working with our partners to identify more unmet medical needs and focus our research where it is needed most.

The uncontrolled chemotherapy-induced nausea and vomiting (CINV), is a common and dreaded side effect of cancer treatments and a major source of impact on a patient's day-to-day quality of life.

The inclusion of two molecules in our product portfolio in the past years contributed to the expansion of the antiemetic arsenal recommended by international guidelines, thus improving the quality of life of patients and allowing them to focus on their cancer treatment plan.

Cancer Therapeutics

Helsinn moved into cancer therapeutics because we identified a real patient need area. Mycosis fungoides (MF) is a rare type of skin cancer that is an incurable, highly symptomatic malignancy characterized by the migration of malignant T-cells into the epidermal layer of the skin in the early stages and into the lower dermal layer and the circulatory system in its advanced stages.

In 2018 Helsinn Group announced the acquisition of the worldwide rights to a product (mechlorethamine/ chlormethine) from Actelion Pharmaceuticals Ltd, an approved and marketed alkylating agent for the topical treatment of mycosis fungoides type cutaneous T-cell lymphoma.

In the US, approximately 15'000 patients are currently diagnosed with stage IA-IB MF-CTCL, qualifying it as a rare or orphan disease. The US Food and Drug Administration has therefore granted it the Orphan Drug Designation (ODD). In Europe, the EMA Committee for Orphan Medicinal Products reported that the number of MF-CTCL patients in European countries was less than 132'000 (<2.6 patients per 10'000).

Pain & Inflammation, Gastroenterology

Nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the management of acute inflammatory pain. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) with over 30-years of history in the treatment of acute pain and primary dysmenorrhea. It is currently licensed in over 30 countries, under various brand names.

Two other historical products are consolidated PEG-based specialties for gastrointestinal lavage and preparation prior to diagnostic examination or surgery. In over 25 years, this effective and safe product has been used in several types of procedures worldwide. The main ingredient is PEG 3350 which acts as laxative with various salts added to maintain the body's electrolyte balance.



Our Science

With the most dedicated researchers, world-class facilities, and highest standards in science, quality, and ethics, we would help fulfill more unmet needs for the patients worldwide.

Over the past years we've reinvested approximately 35% of our revenues in research and development.


Our R&D capabilities are recognized worldwide, from pre-clinical research through all phases of clinical development with proven expertise and focus in cancer care and rare diseases.

The main R&D efforts are concentrated in cancer therapeutics and cancer supportive care. A new generation of compounds acting on the ghrelin receptor for multiple potential indications constitutes our early-phase pipeline, and new cancer care products in various stages of development, including compounds in Phase III clinical development constitutes the late-stage development where there are currently no options available and helping to lift the burden of cancer for our patients.



Our Partnerships

In order to reach out and serve as many patients as possible around the world, Helsinn has built a network of **reliable distribution partners** who commercialize our products in **more than 190 countries**.



To deliver the best possible care to our patients, we engage with a number of our stakeholders to create innovative collaborations. Our aim is to work together with researchers, patients, and advocacy groups in order to foster a transparent communication and interaction and to potentially speed up the discovery process.

Together, we will ultimately accelerate and strengthen achievement of the goal of bringing our products to all those who need it, globally.

Commercial Partnerships

We work closely with our partners to ensure that our collaborative approach and commitment to quality are shared throughout our network. In addition to cultivating long-standing relationships, we provide ready-to-market finished dosage forms and a complete package of services in support of either the product or our partners' local activities. We also help our partners to achieve success with their mission throughout the product life cycle with continuous scientific development, and advice on commercial, regulatory, financial, legal, medical, marketing and market-access questions.

Our direct sales force in the USA, in China and our out-licensing partners share our values and ambition to improve the everyday lives of patients and benefit from constant and tailored support.

Scientific partnerships

We are honoured to continue working with a number of important research centres and world-class universities. During 2019, 2020 and 2021 we built on our privileged relationship with the following institutions:

- **Memorial Sloan-Kettering Cancer Center**, New York, US: characterization of RET-specific inhibitors; Anamorelin in the immune reconstitution after hematopoietic stem cell transplantation
- **University College of Dublin**, Ireland: biomarkers for use of ghrelin agonists and nutritional status to treat cancer cachexia
- **University of Southern Switzerland** – Institute of Oncology Research – PhD program - sponsoring of the Lecture Series program, 10 seminars throughout the year 2020-2021
- **University of Texas MD Anderson Cancer Center**, Houston, US: clinical studies in cancer supportive and palliative care with a focus on fatigue, anorexia/cachexia, chemotherapy-induced neuropathic pain, diarrhoea, chronic nausea and pruritus
- **University of Zurich, University of Lausanne CHUV, University of Lausanne, Switzerland and University of Geneva**: study chlormethine mechanism of action in cutaneous T cell lymphoma; Assessment of the diagnostic potential of multi-harmonic and hyperspectral imaging for cutaneous T-cell lymphomas
- **The European Organisation for Research and Treatment**: Study to determine the aetiology of skin drug reactions with chlormethine gel in early-stage MF
- **Odense University Hospital**, Denmark: evaluate safety outcomes in a gynaecological cancer population receiving concomitant chemo and radio therapy
- **Tufts University**, Boston, US: to investigate the effect of a ghrelin receptor agonist on muscle and bone

Helsinn Cares

Launched in early 2017, Helsinn Cares is a US patient assistance program and voucher program that supports patients in gaining access to their medicine, independently of insurance. We are committed to providing information to support patients and providers with access and reimbursement. The goal is to make patient access easier: Helsinn recognizes that not all patients have access to the medicines that can significantly ease the burden of chemotherapy's side effects and that the process of establishing eligibility can be challenging.

The program works by assigning a dedicated case worker to each patient who will serve as a go-to point able to help resolve benefit and coverage issues, give reimbursement assistance and find co-pay assistance also for uninsured patients.

- **The Lahey Clinic**, Burlington, US: to investigate Anamorelin in cancer related weight loss and loss of appetite
- **Center for Human Drug Research**, Leiden Netherlands: research to describe MF characteristics and explore novel biomarkers with a multimodal patient profiling approach
- **Center for Excellence on Rare Haematological Disease of Children and Adults Cutaneous Lymphoma**, Greece: investigate the mechanism of action and effectiveness of Chlormethine gel in MF patients

Furthermore, we are excited to announce that we added a new partnership to the list thanks to a study on the effects of new ghrelin derivatives in the cardiovascular safety in the rodents with the University of Hong Kong (Hong Kong).

Helsinn values its longstanding and new collaborations with impactful Scientific Societies and patient associations in the field of oncology in order to promote scientific research and education to patients, healthcare professionals and further healthcare stakeholders.

In fact, in 2021 Helsinn supported the following:

Scientific Societies:

- **SIOG**: International Society for Geriatric Oncology
- **SPCC** Sharing Progress in Cancer Care in Cancer
- **MASCC**: Multinational Association for Supportive Care in cancer
- **Tao Conference**
- **Cancer Cachexia** Conference
- **SCWD** (Society on Sarcopenia, cachexia and wasting disorders)
- **ESMO WCGIC**
- **ASCO**
- **EONS**

Patient Associations:

- **CLF** (cutaneous lymphoma foundation)
- **Cholangiocarcinoma** Foundation
- **AMMF** (Alan Morement Memorial Fund)
- **Conquer Cancer** Foundation

Medical Affairs – Highlights

Our first priority remained to stay close to Healthcare Professionals, patients and their families, by providing support in an ethical way according to their needs. More than ever, it was important to be able to timely share new clinical data and to continue establishing partnerships with the medical community, scientific societies, and other stakeholders with the purpose of advancing science together through ethical scientific exchange and educational initiatives. Helsinn continued supporting a fellowship program at Columbia University with the aim of training and educating an aspiring cutaneous lymphoma specialist, focusing on developing important clinical skills needed in the management of mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) patients, through various dedicated research projects.

New compelling data in the area of cholangiocarcinoma, Urothelial cancer, lung cancer, cachexia, cutaneous lymphoma and chemotherapy induced nausea and vomiting were presented at conferences as virtual abstracts, virtual posters or as part of online educational activities.

2021 was also an important year to progress Helsinn path towards implementing patient centric initiatives, which are based exclusively on patients' needs. In particular we continue to evaluate Early Access Programs in several therapeutic areas aimed at offering ethical, compliant and controlled mechanisms of access to investigational drugs outside clinical trials and prior to product launch, to patients with life threatening diseases that have no treatment options available. Helsinn website now hosts an online portal where EAP requests can be submitted directly by patient's physician and are then be carefully reviewed and evaluated by a dedicated internal committee according to the Helsinn Group operating procedures.

Overall, also with the pandemic emergency decreasing, we plan to maintain and further develop the vast majority of the virtual formats we have created, likely complementing them with live participation, thus creating a hybrid model to run Medical Affairs activities, which we believe to be ethical, sustainable and respectful for both internal and external stakeholders, with patients' needs always at the center of our commitment.

Patient Advocacy – Highlights

During the course of 2021, the Helsinn Advocacy strategy has been finalized and further implemented with a focus on patient centric initiatives. Helsinn performed for the first time two patient initiatives (patient workshop on rare tumors and on early-stage MF-CTCL), for internal purposes only. These initiatives were part of a larger advocacy vision that entails integrating patient perspectives and patient initiatives across the whole lifecycle of a product, (from identification of unmet medical needs to the drug development and further expansion).

The objectives of such patient workshops were to:

- Yield an understanding of patient needs and enhance patient education in the field of rare tumors and supportive care
- Generate ideas to support initiatives to make a difference in the patient and caregiver's journey (e.g., patients' platform)
- Drive patient-centric innovation by elevating the patient voice in decision-making processes. Such area is to be further explored and integrated in 2022.

Key Helsinn Advocacy interactions globally are mapped here:

Professional Societies

CONQUER CANCER™
THE ASCO FOUNDATION

ASCO
AMERICAN SOCIETY OF CLINICAL ONCOLOGY

SCWD
SOCIETY ON CARCINOMA CHEMOKINE AND HEMATOPOIETIC DISORDERS

EORTC
European Organisation for Research
and Treatment of Cancer
The future of cancer therapy



APSHO
Advanced Practitioner
Society for Hematology
and Oncology

HOPA
Hematology/Oncology
Pharmacy Association



SIOG
INTERNATIONAL SOCIETY
OF GERIATRIC ONCOLOGY



**EUROPEAN
HEMATOLOGY
ASSOCIATION**

ONS
Where Oncology Nurses Connect

ESMO
GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

Patient Associations



**LEUKEMIA &
LYMPHOMA
SOCIETY™**
fighting blood cancers

**someday
is today**

**CUTANEOUS
LYMPHOMA
FOUNDATION**

**CANCER SUPPORT
COMMUNITY**
A Global Network of Education and Hope



**Patient
Empowerment
Network**

CANCERcare

**LUNG CANCER
ALLIANCE**

**prevent
cancer**
FOUNDATION

Oncology Networks



**CEO ROUNDTABLE
ON CANCER**



**National
Comprehensive
Cancer
Network®**

Some examples of our advocacy activities include

Anna Braglia Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator

The Anna Braglia Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award 2021 was presented to Dr. Patrick Johnson, MD, one of the chief hematology/oncology fellows at the Dana-Farber/Mass General Brigham fellowship program.

The funds from the grant will be utilized to progress Dr. Johnson's proposed study into assessing whether educational videos will have an impact on the patient's knowledge and preference for CAR T-cell therapy, self-efficacy, prognostic understanding, psychological distress, and uncertainty with decisions.

SDA Bocconi and Helsinn explore the new frontiers of mHealth

Helsinn and Bocconi share a common goal: to open new pathways in therapeutic management and in the relationship between patients and healthcare facilities.

After years of collaboration and research, SDA Bocconi and Helsinn have developed LuCApp, a Lung Cancer App (tradename Azalerta™), a mobile application aimed at improving the quality of life of lung cancer patients.

The app allows patients to self-monitor their condition by sending data to the health care provider, which receives an alert whenever abnormalities are recorded. This gives patients more control over their condition, and gives healthcare facilities a better chance of detecting problems sooner.

The original vision for LuCApp was to create an empowerment tool for people with lung cancer and their caregivers. The app is now undergoing a randomized clinical trial in collaboration with three main Italian cancer centers.

The results are expected to be published in 2022.



CONQUER CANCER®

THE ASCO FOUNDATION

Conquer Cancer Foundation/Anna Braglia
Endowed Young Investigator Award
in Cancer Supportive Care

Young Investigator Award

The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of the grant is to fund physicians during the transition from a fellowship program to a faculty appointment.

This is a mentored award and the research project is conducted under the guidance of a scientific mentor. Applications in all areas of cancer research are accepted from U.S. and international applications.

 **HELSINN**
Building quality cancer care together

Quality of Life for Our People

For over 40 years of activity the family values of the owners have been at the heart of Helsinn philosophy.

At Helsinn, we firmly believe that our people are the foundation of our business. In a world that is rapidly changing, our people and their skills are increasingly a key component for our long-term success.

We understand that technology is changing the way we work and we want to adapt and improve to maintain our employee satisfaction; for this reason, we strive to provide a stimulating and enjoyable work environment where our people can thrive.

At the same time, work-life balance is of fundamental importance: we want our employees to develop their careers and to pursue their personal objectives

- Thanks to the expansion of our business, both geographically and in terms of our operations, we have been growing our team in the last few years and at the end of 2021 we employed 502 people (+15% vs. 2015) .
 - In 2021, 41% of management positions were occupied by women (+31% vs. 2015)
 - We have 6 apprentices and during 2021 we employed 7 interns
 - These numbers confirm that Helsinn is a healthy company and a strong employer, creating attractive jobs and economic development in the communities in which it operates.
- At present, there are no bargaining agreements in place at any of our locations.



Total Headcount

GROUP			Companies			
			HHC	HBP	HTU	HPC
502			215	169	102	16
<i>male</i>	269	53.6%	126	85	53	5
<i>female</i>	233	46.4%	89	84	49	11
164			61	28	64	11
<i>male</i>	96	19.1%	38	16	39	3
<i>female</i>	68	13.5%	23	12	25	8

of which in Management roles:

Employees Turnover (including voluntary leaves, interns and apprentices):

55	11.0%	12	29	11	3
		6%	17%	11%	19%

Hours of Trainings

<i>provided by year:</i>	21808	13068	5000	3720	20
<i>day per person:</i>	5.4	7.6	3.7	4.6	0.2

41% of
management
positions
occupied
by women

Age Group

<30	43
30-50	271
>50	188

Years of Services


<1	55
1-5	174
5-10	85
10-15	70
15-20	70
20-25	37
25-30	9
30+	2

Anniversaries


10 years	17
20 years	4
25 years	3
30 years	0

Job Satisfaction, Motivation, Retention

TOTAL HEADCOUNT by gender




**Total Employees
Gender distribution 2021**



■ 269 Males
■ 233 Females

**Management
Gender Distribution 2021**



■ 96 Males Mgmt
■ 68 Females Mgmt

In our history we have grown and succeeded beyond our expectations. This would never have been possible without the essential contributions of our employees worldwide. We are therefore proud to see a high degree of commitment and to confirm a low turnover rate despite the high competition for qualified employees, particularly in our Swiss and Irish subsidiaries.

The loyalty of our people is demonstrated by the average length of service. Every year we celebrate our colleagues who reach their 10th, 20th, 25th working anniversaries.

In 2021 three employees surpassed the remarkable target of 25 years of service.

This is possible thanks to a leadership team that empowers high achievement while nurturing the core values of respect and integrity. We make sure there is equity amongst peer compensation in every employee group.

Our remuneration system is therefore based on objective professional criteria, such as skills level, knowledge, experience and qualifications. Globally, 18% of our staff has more than 15 years of service.

Temporary employees are offered equitable conditions comparable to those of full-time employees in terms of remuneration and benefits (such as health insurance, sick pay and pension fund contributions).



Equal pay and opportunity have always been part of our culture: in Switzerland, we are an Equal-pay certified company.

More and more in 2021 Helsinn has been engaged in bringing good employment practices in Switzerland and worldwide, being active through roundtables, interviews and webinars around subjects of Employee wellbeing.

In addition, we have been working constantly with local partners to promote healthy practices, such as the canteen provider, medical service provider.

Training

Every year Helsinn makes a considerable investment in regular internal and external training in order to continuously develop our employees' professional, managerial and personal skills. Training is required across all levels of our company, from our apprentice programs, to leadership and strategy courses for our management. In 2021 our training activity reached the unprecedented level of 2720 days of training, an average of 5.4 days per person.



A cross-functional team from the headquarter attended a training at the Swiss-Italian applied science University SUPSI, about agile project management, supporting Helsinn digital transformation.

Safety, Health & Wellness

Providing a safe and healthy work environment for employees and contractors has been absolutely crucial during 2021. We have guaranteed a total commitment to providing the safest work environment possible across our global business and to safeguard all our employees and their families, considering the employment requirements as well as the external pandemic context.

During 2021 we registered one work-related accident with a 1 to 5 days absence.

Since the beginning of the pandemic, we have taken the necessary measures, exceeding the government guidelines, to guarantee all hygiene and social distancing measures. All employees received and were trained in remote work Standard Operating Procedures by December 2020, and an e-learning platform was set up for technical training, GMP and HSE procedures. All subsidiaries updated their handbooks with remote work policy and health management.

In 2021 we gradually returned to the 'new' normal, with hybrid working and necessary travel restrictions.

In Ireland, from October to December, flu vaccinations were administered on site, and a promotion campaign for Covid-19 Booster vaccinations was carried out with the support of a local partner.

Among the many initiatives carried out to support our employees during this very difficult period we can highlight

- Mindfulness meditation courses, mental health and well-being training in Switzerland and Ireland
- Virtual appointments with doctors, psychologists and financial advisors, remote Pilates and yoga classes in Ireland
- Appointment with physiotherapists in Ireland
- An upgrade of the wellness walk path at HBP




Helsinn's Swiss HQ and factory received the Family Score Award for the period 2020-2022, by the Pro Familia Organization, highlighting the family-friendly nature of the Company.

The award showcased the fact that employees are highly motivated and have high expectations as well as highlighting areas of possible improvement such as remote working and initiatives for family work-life arrangements, such as childcare.

Our employees have access to benefits that exceed local labor laws, according to qualification and seniority within the organizations.

Below a few examples:

- flexible working time
- teleworking
- job-sharing policy
- continuous education and training
- company car or car allowance
- mobility plan, contribution to public transportation and electric bikes
- charging stations for plug-in cars
- subsidized canteen or meals allowance
- kindergarten contribution
- yearly medical consultation and check-up
- employee assistance program, supplemental pension fund
- loyalty awards



Quality of Life in Our Communities

We've always been involved in the communities where we live and work. As good corporate citizens, we want to broaden our impact beyond our business and give back to society by contributing to the progress of the regions where we are based. We support a number of programs spanning from sports to education, culture, and charities, either financially or through active involvement.

During another challenging year our engagement remained high: we maintained our partnerships with charitable, cultural and social institutions despite the continued restrictions imposed by the pandemic.



Fondazione Gabriele e Anna Braglia

Founded in 2014 by Anna and Gabriele Braglia, the foundation is dedicated to cultural and educational art and organizes, supports and promotes art exhibitions, conferences and a series of cultural activities. After having spent the last 50 years exploring their passion for art and growing their collection, the founders decided to share their collection with a wider audience.

The collection, which boasts several works by prominent artists such as Picasso, Modigliani, Klee, and Kandinsky among others, is on display in an exhibition space on the Lugano waterfront and is open to the public.

More information can be found at
www.fondazionebraglia.com



Foundation New Flower in Africa

In 2011 the Braglia family founded the New Flower Foundation in order to support education and vocational training in Africa. After 10 years, more than 25'000 students were enrolled in the Foundation's schools marked the beginning of many new projects, which now total 26 across 7 countries: Ethiopia, Ghana, South Sudan, Gabon, Congo, Togo and Madagascar.

The aim of the foundation is to promote basic education for all children in the hope of reducing the illiteracy rates in these countries and to fight social injustice. The work on the ground is carried out with the help of well-established and recognized local organizations in order to guarantee the long-term sustainability of the projects.

More information can be found at
www.nuovofioreinafrica.org

Greenhope / Corsa della Speranza (Terry Fox Run)

As a company with deep roots in the canton of Ticino, Helsinn makes it a point to support the battle against cancer at the local level.

Helsinn donates to Greenhope and the local Terry Fox Run. The former is a charity which organizes sporting events with the aim of providing children affected by

cancer and their families a moment of diversion. The latter is celebrated in more than 50 countries around the world and is organized each year in order to raise money for cancer research.

In 2021 the run was cancelled, but a several activities took place in different locations.

Other initiatives that we regularly support are:

- Leukemia Lymphoma Society
- Irish Cancer society
- ARC Cancer Support Centres Ireland
- St. Francis Hospice, Dublin
- Technological University Dublin - The Jackie Bradley Award (in memory of our colleague)

Other Associations and Forums

Besides offering our support to philanthropic initiatives, we believe that we can provide an important contribution to the community by being actively involved in a number of associations and forums.

We are members of:

- Associazione Industrie Ticinesi (AITI) - Switzerland
- Bio NJ - US
- Camera di Commercio Industria Artigianato (Cc-TI) - Switzerland
- Consultancy Forum for Pharmaceutical Engineers - UK
- Dublin Chamber of Commerce - Ireland
- Engineers Ireland - Ireland
- Farma Industria Ticino (FIT) - Switzerland
- International Society for Pharmaceutical Engineerin-US
- Irish Business and Employer's Confederation - Ireland
- National Industrial Safety Organization - Ireland
- New Jersey Business Industry Association (NJBIA) - US
- New York Pharma Forum - US
- Parenteral Drug Association - US
- Pharma Chemical Ireland - Ireland
- Swiss Irish Business Association - Ireland



We are proud to
be active in the
communities
where we live
and operate

Quality of Life in Our Environment

During 2021 the uncertainties related to the pandemic continued, albeit less intense despite the operational constraints. We continued to improve our environmental performance and introduced a series of measures in this area.

Already in 2020, we upgraded the analysis of our environmental impacts: we started to measure the total carbon footprint of our operations through an assessment of the entire value chain emissions according to GHG Protocol and ISO 14064 standards.

Through the purchase of high quality, Gold Standard certified Carbon Credits in 2021 we became a Certified Carbon Neutral company. We plan to continue on this path and in 2022 we will compensate again the emissions we are unable to reduce.



Highlights

- We have further diminished our total energy consumption vs. 2020
- 43% of our energy – and 80% of the electricity – is obtained from renewable sources
- We don't use any heating oil, natural gas and electricity are our only sources
- In all our offices and our factory in Ireland, we have put in place stringent measures to reduce the environmental footprint of our operations
- in Ireland 100% of the electricity comes from renewable sources
- in Ireland and at our HQ in Lugano we have installed photovoltaic panels
- EV charging stations were installed in Ireland and Switzerland, using electricity generated by the new PV panels
- Air travel was drastically reduced
- In all our offices and factories, ventilation was substantially increased in order to guarantee the maximum ventilation of the premises
- Our water consumption is stable


The calculations for energy, water and emissions that follow do not include our offices in China due to the difficulty of collecting reliable data. However, since the impact of these offices on the total is extremely limited (below 0.5%), the resulting figures represent the group's performance with a very high level of accuracy.

Energy

Total Energy Consumption (kWh)

	2015	2020	2021	Var. 2021 vs 2015	Var. 2021 vs. 2020
Total energy consumption	12'456'506	13'234'541	12'915'251	3.7%	-2.4%
Total energy per capita	29'309	25'698	25'728	-12.2%	0.1%
From renewables	1'463'757	5'654'911	5'591'367	282.0%	-1.1%
% from renewables	11.8%	42.7%	43.3%	268.4%	1.3%
Renewable energy per capita	3'444	10'980	11'138	223.4%	1.4%
CO2e energy emissions (tons)	2'436	1'114	1'086	-55.4%	-2.5%

Energy consumption [kWh]



We use two sources of energy: natural gas (Dublin, Lugano HQ, USA), and electricity (all locations).


We continue to rely on more renewable sources and to reduce the energy intensity per employee. Thanks to the use of 100% renewable electricity in Ireland, an improved electricity mix in Switzerland in 2021 our overall quote of energy coming from renewable sources reached 43%, a remarkable result and a big step forward compared to the 2015 baseline (+282%).

The energy intensity remained stable, mostly due to the increased HVAC activity to guarantee a very intensive ventilation in our Irish and Swiss locations: This has been a preventive measure introduced in February 2020 to reduce the risk of COVID 19 transmission of indoors. Despite this issue, the intensity of renewables grew 223% vs. the 2015 baseline, while the overall energy intensity decreased by 12%.

Water

	2015	2020	2021	Var. 2021 vs. 2015	Var. 2021 vs. 2020
Total water consumption m ³	21'097	13'503	13'476	-36.1%	-0.2%
Total water consumption per employee (Intensity) m ³ /emp	50	26	27	-45.9%	3.0%

Trends – Water Consumption, per employee




In 2021 our overall water consumption remained stable vs. 2020. The level of overall consumption and the intensity remained overall stable during the past 2 years but showed a clear improvement vs. baseline 2015 thanks mainly to important investments in the HVAC systems.

Industrial Waste

Waste (tons)	2018	2020	2021	Var. 2021 vs 2018	Var. 2021 vs. 2020
Hazardous	5.1	6.2	7.0	37.2%	13.1%
Hazardous (recovered)	4.9	5.2	4.3	-12.2%	-17.3%
Non hazardous	230.2	209.7	207.4	-9.9%	-1.1%
Non hazardous (recovered)	221.0	198.5	183.7	-16.9%	-7.5%
Total waste recovered	225.9	203.7	188.0	-2.2%	2.4%
Total waste tons per employee	0.44	0.42	0.43	-3%	2%

Waste [tons]




The 13% growth in hazardous waste - waste with properties that make it dangerous or at risk of having a harmful effect and requires a specialized treatment for its disposal – is caused by a surge in the use of solvents at the Irish factory. The total waste generated remained stable, while the waste recovered or recycled decreased by 7.7%.

Paper

Photocopy and Printing Paper (Kg)

	2015	2020	2021	Var. 2021 vs. 2015	Var. 2021 vs. 2020
Paper	10'234	7'451	4'824	-53.4%	-35.3%
Kg per employee	24.1	14.5	9.6	-60.2%	-33.6%

Paper [Kg]



All our Business Units use FSC (Forest Stewardship Council) and PEFT (Program for the Endorsement of Forest Certification) certified paper. These are the two most important paper certification bodies which ensure that products come from well- managed forests that provide environmental, social and economic benefits.

In the past few years, we were able to considerably reduce our purchases of paper thanks to a more careful management of the printing system and improved digitization of different workflows. Of particular significance was the kick-off of the Paperless project at HQ in 2017 which led to a substantial reduction in the usage of printing paper.

Examples a of
Sustainability
initiatives at HBP



Sustainability In Practice

Behind the Scenes – Boiler Upgrades

Heating the site for both comfort and processing is a significant user of gas energy. Where we see opportunities to optimise the boiler system we take it as the payback is significant...

The Proposal:


- The boilers operate at 108°C during processing hours.
- Due to restrictions on the system we couldn't lower the temperature significantly after hours.

Solution:

- Install expansion vessels to allow a lower set back temperature.
- Install access platform to allow the expansion vessels be placed at a height (the boiler house has restricted space).
- Monitor and tweak the system to optimise usage.

Outcome – One Year On:

- 1.2 million kWh saved (23% less than previous year).
- 250 tonnes less carbon produced (7% of site footprint).
- Boilers are being used 13% more efficiently.
- Cost equivalent of €60,000.



Sustainability In Practice

PV Panels

To Reduce our Carbon Footprint and to Integrate Green Energy into the Site Helsinn invested in the Installation of a Photovoltaic Panel Array.

The Proposal:

- Through energy initiatives on site HBP received a rebate from our energy provider of €120,000. The company was keen to invest this money into green energy for the site.

Solution:

- Helsinn installed a 50KW PV panel array on our roof.
- The design optimised the sun intake over a 12 months.
- Installation by an Irish company.

Outcome:

- 120000kWh generated to this point.
- Helsinn off-set 61 tonnes of carbon – equivalent of 160 return trips to Lugano.
- Based on the success of the initial programme Helsinn has installed a further 132kW of generation capacity.



CO₂e Emissions


It is an imperative for each company to be able to understand the magnitude of its emissions, where they are generated along the value chain and to develop a plan in order to reduce them or, when reduction is not possible, to compensate the excess through a verified and effective program.

The first step is to establish an inventory of all emissions in the whole value chain of a company. To do so we collected a series of data according to the standards established by the GHG Protocol and the ISO 14064-1 standards. Based on the results, a company can then develop an emission reduction target and a path towards Net Zero.

Since 2012 Helsinn has been measuring Scope 1 and business travel emissions, and implemented energy savings and CO₂e emissions reduction measures. We are fully aware of the importance of decarbonizing our activities while we pursue our economic growth and social impact, and we believe it is not only possible but our duty to decouple them.

Until 2019 our measurements were limited to the direct CO₂ emissions caused by energy consumption at Helsinn locations and by owned assets (Scope 1), as well as from business travels. An important reduction both in absolute terms as well as in intensity has been achieved through a constant monitoring of our emissions as well as important investments to improve the energy and CO₂e performance of our buildings and our processes: we were able to reduce our Scope 1 emissions intensity (Tons of CO₂e/employee) by 55% from base year 2015 to 2020.

With the intention of continuing our path towards decarbonization in 2020 we decided to upgrade the evaluation of our environmental impacts. We measured – and certified - with the help of an independent organization, the total carbon footprint of our operations through an assessment of the entire value chain emissions, in accordance with the GHG Protocol and ISO 14064 standards.



The Greenhouse Gas Protocol (GHG-P) provides the following definitions:

Scope 1 - all direct emissions that arise from sources that are owned or controlled by the reporting entity. They include fuel combustion, company vehicles and fugitive emissions.

Scope 2 - covers indirect emissions from the generation of purchased electricity, steam, heating and cooling consumed by the reporting company.

Scope 3 – all indirect emissions not included in Scope 2 that occur throughout the Value Chain of an organization, including both upstream and downstream emissions. It includes impacts generated in 15 categories, for example:


- Energy consumption
- Business travel
- Employee commuting
- Chemicals used in production
- Water consumption
- Waste disposal
- Logistics (up- and downstream)
- Meals served in canteens

2021 Results
CO₂e footprint, by category (tCO₂e)

Category	tCO ₂ e (2020)	tCO ₂ e (2021)	Var. 2021 vs. 2020
Heating (Natural Gas)	1201	1175	-2%
Business travel	740	765	3%
Commuting	1261	645	-49%
Electricity	358	340	-5%
IT Hardware & Printing Paper	69	222	222%
Waste	129	72	-44%
Freight	11	61	452%
Canteen	87	58	-34%
Chemicals	0	15	-
Cleaning services	11	11	-5%
Water	6	6	-3%
Total	3873	3370	-13%




CO2e footprint, by category




CO2e footprint: Scope 1, 2, 3

Scope	TOTAL		CHE		IRL		USA		CHN	
	tCO2e	% of total	tCO2e	% of total	tCO2e	% of total	tCO2e	% of total	tCO2e	% of total
Scope 1	1175	34.9%	117	10.0%	1055	89.8%	3	0.2%	0	0.0%
Scope 2	340	10.1%	1	0.3%	3	0.7%	334	98.1%	3	0.9%
Scope 3	1855	55.0%	427	23.0%	552	29.8%	873	47.1%	3	0.2%
Total	3370	100%	545	16.3%	1609	47.8%	1210	35.9%	6	0.2%

% of Co2e footprint by scope:



% of CO2e footprint by country:



Analysis

It’s important to remember that CO2e inventories are not perfect, but a best estimate of the emissions caused by an organization throughout its value chain, according to the universally accepted standards ISO 14064 and GHG Protocol. While Scope 1 and 2 are very accurate, Scope 3 are less precise due to the difficulties of including, and measuring, all the aspect and variables across a company’s value chain. Nevertheless, having such an inventory is the mandatory starting point to decarbonize, by defining CO2e reduction measures and engaging in the Science Based Target Initiative.

Scope 1 emissions

The totality of scope 1 emissions (company facilities and owned vehicles) is generated by natural gas consumption.

	TOTAL	CHE	IRL	USA	CHN
Total tCO2e	1175	117	1055	3	0
tCO2e (%)	100.0%	10.0%	89.8%	0.2%	0.0%

Scope 2 emissions

Scope 2 emissions represent 10% the total. They are essentially due to the high percentage of electricity generated from unverified sources used by the US subsidiary (98% of total scope 2 emissions).

A reduction of Scope 2 emissions will be reached once HTU moves to the new LEED certified offices in 2022.

Scope 3 emissions

The activities that make up scope 3 represent 55% of the total CO2 emissions.

Highlights:

- Business travel is the main source of scope 3 emissions, and the second overall. Further reducing non-essential travels, and switching to a more energy-efficient US fleet can substantially reduce the CO2e emissions
- Commuting with private vehicles is the second source of scope 3 emissions, and the third overall. Carpooling, home office flexibility and incentivizing public transport subsidies are the available tools to reach a reduction

The five principal sources of emissions are key priorities for our efforts: we are currently revising our carbon strategy and, in light of the results of this work, will redefine our priorities and establish our Path to Net-Zero.



We are
redefining our
priorities and
establishing our
Path to Net-Zero.



CERTIFIED SDG IMPACTS



PROJECT TYPE



Energy Efficiency - Domestic

STATUS



Gold Standard
Certified Project

Carbon Neutral – 2021

For the second year, we are a Carbon Neutral company. We decided to compensate our total emissions with the purchase of high quality, Gold Standard certified Carbon Credits. This year, we selected a Safe Community Water Supply project in Rwanda.

Improved Kitchen Regimes: Kayonza District Borehole Project, Rwanda

This Micro-Scale Voluntary Project “Improved Kitchen Regimes: Kayonza District Borehole Project, Rwanda” supports the provision of safe water, using borehole technology, to hundreds of households within the Kayonza District. By providing safe water, the project ensures that households consume less firewood during the process of water purification and as a result there will be a reduction in Carbon Dioxide (CO₂) emissions from the combustion process.

<https://registry.goldstandard.org/projects/details/976>



We are delighted to confirm the retirement of

3370 Verified Emission Reductions (VERs)

on 02/08/2022

Retired on behalf of Helsinn SA, For Scope 1,2,3, year 2021

*These credits have been retired, saving **3370** tonnes of CO₂ emissions from being released into the atmosphere.*

Thank you for investing in a safer climate and more sustainable world.

[View retirement](#)


Retirement certificates are hosted on the Gold Standard Impact Registry, [view your certificate](#).

Gold Standard | Chemin de Balexert 7-9 1219 Châtelineau, International Environment House 2, Switzerland | goldstandard.org +41 22 788 70 80, help@goldstandard.org

Acting Responsibly

Helsinn is committed to ethical, social, and environmental responsibility. We always operate to ensure honesty, high-quality standards, and integrity in everything we do. These principles are strongly embedded in our culture and we have always based all our activities on these standards.

In order to support our international growth and to strengthen even more our culture of responsibility and our resources in this area of ever-increasing complexity, in 2021 we have carried out an extensive awareness and training campaign to support our employees on several topics (i.e.: ethical behaviour, anti-corruption, cyber security, data protection).



The Compliance Program

To conduct its business with ethics and integrity, Helsinn has established and maintains an effective Compliance Program. This program has been developed in accordance with applicable laws, regulations, Helsinn Policies and industry codes.

Helsinn's Compliance Program includes:

- Compliance Officers and Business Ethics Board (BEB) charged with the responsibility for operating and monitoring the Compliance Program
- Code of Conduct, Policies and Procedures detailing the Company's commitment to compliance and setting forth the ethical and compliance principles applicable to all employees
- Regular education and training programs for applicable employees
- Easy access to the Compliance Officers by all employees. This includes:
 - A reporting process to collect concerns and ask questions
 - Policies and procedures to protect the anonymity of employees who raise concerns (as applicable) and to prohibit any form of retaliation against them
- Use of audits and routine monitoring activities to monitor compliance and identify and address risks
- Enforcement of compliance obligations through policies that include corrective measures or penalties for non-compliant behavior
- Mechanisms to promptly and properly investigate and respond to reports of non-compliance, including processes to initiate corrective measures and to report offenses to the relevant authorities where appropriate

The Helsinn Code of Conduct

The Code of Conduct is a tangible demonstration of the level of professionalism that Helsinn wants to achieve in its activities and expects from all its directors, employees, contractors and business partners, whether permanent or temporary staff.

As an organization committed to being in compliance with the legal, ethical, environmental and social responsibility, we believe in the principles set out in our Code of Conduct. These responsibilities are applicable to all activities involving Helsinn or anyone acting on behalf of or in concert with the Group to allow for a sustainable growth of our business.

The Helsinn Compliance and Quality Manual

The purpose of the Manual is to ensure that the principles, laid down in the Helsinn Code of Conduct as well as in international pharmaceutical industry regulations and practices, are properly translated into Group rules which can be effectively communicated to and applied by all Personnel and Companies of the Helsinn Group.

Compliance Policies and Procedures

The compliance Policies and Procedures are detailed in the following documents:

- The Gold Book - A synopsis of Helsinn Policies on Business Conduct Standards and Ethics.
- The Red Book - Global Principles for all interactions with Healthcare Professionals and Patients.
- The Third-Party Code of Conduct – It describes the principles that we expect our business partners to follow in the conduct of their business. This expectation represents an important component of our Third parties' evaluation and selection. Third parties should also apply these (or similar) principles to the partners with whom they work when providing goods and services to Helsinn.

Quality

Helsinn commits to a culture of quality and regulatory compliance for its products and services. Helsinn expects all personnel and external collaborators to understand the importance of applying ethical, honesty and integrity principles to all their actions and decisions in order to protect patients.

- We regard quality as a priority in all aspects of our work and as a competitive advantage that creates value.
- We develop, manufacture and deliver high quality, safe and effective medicines in order to make Helsinn a better, more reliable and valuable partner for patients, regulators and Business Partners.
- We commit to meet regulatory expectations and adhere to applicable laws in all our activities.
- We take all decisions in the best interest of patients.
- We consistently apply continuous improvement by regularly taking into consideration feedback from the market, patients and Business Partners as well as technology advancements.
- We communicate with key stakeholders in full transparency and with a spirit of collaboration.

Helsinn believe that the compassionate treatment of animals is extremely important, and we comply with all applicable laws, regulations and codes on the treatment of animals. Helsinn have in place systems and processes to ensure full traceability of the products and services we provide, including of ingredients and raw materials.

We continuously develop new products for our group and for third parties; hence we adopt new technologies and install new equipment at our manufacturing sites. Due to this ongoing innovation, an impressive program of quality audits has been implemented by several agencies, aimed at certifying Helsinn's compliance to Good Practices (GxP) rules and regulations.

- | | | |
|---|--|--|
| • US FDA – Current Good Manufacturing Practices – HBP Dublin | • ISO 13485 certification for Medical Device – HHC-Lugano | • South African Health Ministry – HBP Dublin |
| • HPRA Ireland – Pharmacovigilance audit – HBP Dublin | • Investigational Medicinal Product (IMP) Licence – European Medicines Agency – HBP Dublin | • Ministry of Food and Drug Safety (MFDS) South Korea – HBP Dublin |
| • ANVISA Brasil – Current Good Manufacturing Practices – HBP Dublin, HHC Lugano | • Russian Health Ministry – HBP Dublin | • Pharmaceuticals and Medical Devices Agency (PMDA) Japan – HBP Dublin |



On average, we have a quality, safety or environmental protection inspection approximately every month at one of our locations. In Ireland, Helsinn Birex Pharmaceutical is a member of the Responsible Care Initiative, which is the global chemical industry's unique initiative to improve health, environmental performance, enhance security, and to communicate with stakeholders about products and processes.

Data Protection and Privacy

Helsinn protects the right to privacy and data protection of any individuals, both of employees and of third parties with whom it interacts. Helsinn is committed to comply with all applicable data protection laws, regulations and codes in the countries in which it operates and, to this end, has set up an appropriate data protection and privacy system for the processing of personal and sensitive data, including definitions and implementation of relevant policies and procedures.

- We process personal data fairly and lawfully in compliance with data protection requirements.
- We consider additional data protection requirements and we use special care when processing special categories of data (i.e., sensitive personal data).
- We process personal data only for specified, explicit, lawful and legitimate purposes.
- We only process personal data for the purposes for which they were authorized.
- We only process accurate, complete and up-to-date personal data as appropriate to the purposes for which they are collected.
- We only keep personal data in a form which permits identification of the data subject for as long as necessary for the permitted purposes.
- We guarantee the exercise of the rights of individuals in relation to their personal data, according to authorizations and applicable laws.
- We only disclose personal data to trusted third parties who have been authorized or otherwise mandated by applicable laws.
- We only transfer personal data to countries with equivalent level of protection or if all the necessary safeguards, provided by applicable laws, are in place.
- We retain personal data in accordance with Helsinn's records retention policy as well as data protection and privacy policy, for the limited purpose or purposes and the limited time for which they are authorized to be collected and processed, in accordance with applicable local and international regulatory requirements.

Corporate Governance

Board of Directors

The Board of Directors is responsible for the overall direction, supervision and control of the Group and determines the principles of the business strategy and policies. The Board exercises oversight over the Group's subsidiaries and is responsible for ensuring the establishment of a clear Group governance framework to effectively steer and supervise the Group activities.

This takes into account also the material risks to which the Group and its subsidiaries are exposed. The Board, under the leadership of the Chairman, decides on the strategy of the Group upon recommendation of the Group CEO,

and exercises the ultimate supervision over management. In addition, three Committees assist the Board in the performance of its duties and report directly and periodically to the Board (Audit, Risk and Compliance Committee; Nomination and Remuneration Committee; Strategic Committee).

To assess the independence of the Board members, the board has applied the independence criteria of the Swiss Code of Best Practices for Corporate Governance published by EconomieSuisse, as well as the rules of the NYSE and Nasdaq in determining the definition of independence.



Riccardo Braglia
Executive Chairman



Giorgio Calderari
Group CEO and Board Member



Paolo Bottini
Board Member



Gabriele Edoardo Braglia
Board Member

Eric Cornut
Board Member

Francesco Granata
Board Member

In general, a director is considered independent if the director:

- is not, and has not been for the prior three years, employed as an executive officer or in another function at the Group or any of its subsidiaries;
- is not, and has not been for the prior three years, an employee or affiliate of our external auditor; and
- does not maintain a material direct or indirect business relationship with the Group or any of its subsidiaries.

The Board is currently composed by three internal Directors

- Riccardo Braglia, Giorgio Calderari and Gabriele Edoardo Braglia - and six independent directors.

In January 2022 Gabriele Braglia, Helsinn's founder and Chairman until end 2021, became Honorary Chairman, Riccardo Braglia was appointed Executive Chairman, and Gabriele Edoardo Braglia, son of Riccardo Braglia and the fourth generation at the helm of the company, and Siddharth Kaul, a pharma veteran with 40 years of experience, joined the Board.

The operational leadership of the Group has been taken over by Giorgio Calderari as CEO.



Lonnie Moulder
Board Member

Mary Lynne Hedley
Board Member

Siddharth Kaul
Board Member



Senior Executive Committee as per Sept 2022

The management of the Group is delegated to the senior executive team under the leadership of the Group CEO. Duties and competencies of the Executive Committee are specified by the Group CEO in accordance with the business strategy and policies. The Executive team manages the operations of the Company and the overall business of the Group.



Riccardo Braglia
Executive Chairman



Giorgio Calderari
Group CEO



Melanie Rolli
Group Chief
Operating Officer



Konrad Wilson
Group CFO



Matteo Missaglia
Group General
Counsel & CLO



Georg Büchner
Group Chief Business Officer



Sergio Cantoreggi
Group CSO &
Global Head of R&D



Roberta Cannella
Group Chief
Manufacturing Officer

Strong and experienced Senior Management team

An outstanding management team committed to Helsinn's core values



Deirdre Hurley

Local GM,
Helsinn Birex Pharmaceuticals
Ltd., Ireland



Paul Rittman

Local CEO,
Helsinn Therapeutics (U.S.), Inc., USA



Enrico Magnani

Local GM,
Helsinn Pharmaceuticals (Beijing) Co., Ltd., P.R.C.



Cristina Marenzi

Group Head of
Human Resources



Matteo Santi

Group Compliance Officer
and Group Head of
Compliance and Quality



Roberto Lazari

Group Head of ICT and Digital




Andrea Pontiggia

Head of Intl. Commercial Business

Economic value creation

Pursuing a Triple Bottom Line is our guiding principle: we aim at generating profits in order to pay above average salaries and to keep investing as necessary to be competitive in the industry, but not without taking into consideration our social and environmental externalities. Our contribution to society comes in different forms, one of which is the direct and indirect economic impact of our activities. The main beneficiaries of our redistributed value added are our employees, our suppliers, the governments and our shareholders, and charitable contributions. This way, we redistribute a large part of the value we create. Considering our ties to the territory and the family values that have distinguished our approach to business, we strongly believe that it is our duty to support the local economies where we work and live. For this reason, the unwritten rule at Helsinn is that whenever possible, we support local suppliers of goods and services.



The financial principles that govern Helsinn guarantee that we remain economically stable, independent, and flexible. As the Group evolves from a purely cancer supportive care company and expands into the field of cancer therapeutics we have been investing heavily in R&D, with more than 20% of turnover invested over the past five years. We also aim to generate profits in order to redistribute the value we create back into our employees, our suppliers, governments, our shareholders and charitable contributions.

Financial Highlights

As a privately-owned company, our policy is to not publish a detailed account of our financial figures.

In terms of economic value creation, in the last years we have evolved from a purely cancer supportive care company and expanded into the field of cancer therapeutics. We have been investing heavily in R&D and increased our commercial portfolio with the acquisition of an approved and marketed product.

In the past five years in excess of 26% of turnover was invested in R&D, and around 30% in personnel salaries and benefits. Diversification of our R&D pipeline, of our product portfolio and our geographical footprint have remained our main business targets in 2021, together with guaranteeing our operations continuity.

With reference to the turnover trend of recent years, as represented in the following chart, the data analysis clearly shows how the company is diversifying its business in terms of geography.

Net revenues by geographic areas (mln/CHF)

	2017	2018	2019	2020	2021
Geographic areas	%	%	%	%	%
USA	57%	30%	24%	21%	25%
EU	17%	32%	40%	31%	17%
JP	15%	19%	18%	25%	18%
CN	1%	1%	5%	6%	17%
RoW	10%	18%	13%	17%	23%

In excess of
20% of turnover
invested in R&D
over the past 5
years

In excess of
30% of turnover
invested in
personnel salaries
and benefits
in 5 years

Helsinn and the SDGs

In 2015, more than 150 international leaders met at the United Nations to launch the 2030 Agenda for Sustainable Development and the 17 Sustainable Development Goals (SDGs) with the objective to end poverty, combat inequality, and achieve social and economic development.

The SDGs are universally applicable, meaning that all countries and organizations must make a contribution to achieving the goals based on their capacities, impacts and goodwill. As signatories to the 2030 Agenda, all countries where Helsinn operates have put

in place national strategies to achieve the targets to which they formally committed. Helsinn recognizes the fundamental importance of this initiative: since 2016 we have integrated the SDGs in our sustainability strategy. Through our activities we are contributing towards the achievement of 10 goals, as described in the next page.

We are aware that measuring a company's contribution based on the SDGs is a challenging task: for this reason, we will introduce a formal monitoring in our revised sustainability strategy from 2022.

SUSTAINABLE DEVELOPMENT GOALS

17 GOALS TO TRANSFORM OUR WORLD





Creating a better Quality of Life for our patients and our people is at the core of our culture. We do so by providing top

quality, effective and value-based therapies and making them accessible to cover the patients' needs all over the world. We safeguard and promote the health, safety and well-being of our employees through numerous initiatives and we sponsor every year sport and leisure activities in the communities where we operate. We contribute towards the achievement of the Goal through the purchase of certified Carbon Credits



We support education in our communities and in emerging countries through scholarships and partnership with

NGOs. Particularly remarkable is our engagement with New Flower In Africa, an NGO founded and led by our CEO and his wife Giuseppina Giavatto Braglia which provides quality education to more than 25'000 children and young adults in Etiopia, Sud Sudan, Gabon, Congo, Ghana, Togo and Madagascar. www.nuovofioreinafrica.org



We constantly improve the efficacy in the use of this precious resource in all our buildings and plants, and monitor care-

fully the ratio of water usage vs. production output to guarantee our efficiency. We contribute towards the achievement of the Goal through the purchase of certified Carbon Credits



We constantly improve our energy efficiency and, in 2020, we have once again increased the share of renewables in our energy mix



Every year, we expand the distribution and create new partnerships with various organizations, we create job opportunities in our locations across three continents and provide superior working conditions, compensation and an inclusive and rewarding working environment for our employees



We continuously improve the efficiency of our buildings, of the technologies we use and of our chemical processes in order to minimize the footprint from the production of our therapies and our supply chain



We support SDG 10 through our Patient Assistance Program and Voucher program in the US, as well as our sponsorship of charitable and educational



initiatives as detailed under SDG 4 We carefully monitor the GHG emissions of our operations, implement reduction

measures, and invest in emission-reducing technology. Even though our factories have a relatively low GHG impact, we nevertheless constantly strive to reduce it by analyzing our value chain and monitoring our efficiency. We contribute towards the achievement of the Goal through the purchase of certified Carbon Credits



We support SDG 16 through our compliance program, which provides a robust approach to ethics and accountability. In 2020

we have further upgraded our Compliance program to strengthen our competencies in this area, and all our employees receive extensive mandatory training



Through its Cancer Gold Standard Accreditation Helsinn has partnered with the CEO Roundtable on Cancer to fight cancer

and save lives, and through programs that promote cancer prevention, early detection and access to quality care together with our international partnership we strengthen our cooperation and contribution towards the attainment of the SDG

Acronyms List

AITI	Associazione Industrie Ticinesi	HPRA	Health Products Regulatory Authority
AML	Acute Myeloid Leukaemia	HQ	Headquarters
AMMF	Alan Morement Memorial Fund	HSE	Health, Safety & Environment
API	Active Pharmaceuticals Ingredient	HTU	Helsinn Therapeutics (US), Inc
ANVISA	Agência Nacional de Vigilância Sanitária (Brazil)	HVAC	Heating, Ventilation & Air Conditioning
B2B	Business to Business	IND	Investigational New Drug application
B2C	Business to Consumer	ISO	International Organization for Standardization
BEB	Business Ethics Board	LEED	Leadership in Energy and Environmental Design (green building certification)
CEO	Chief Executive Officer	MASCC	Multinationale Association for Supportive Care in Cancer
CFDA	China Food and Drug Administration	MF-CTCL	Mycosis Fungoides T-Cell Lymphoma
CHUV	Centre Hospitalier Universitaire Vaudois	MFDS	Ministry of Food and Drug Safety (Korea)
CINV	Chemotherapy-Induced Nausea and Vomiting	NCCN	National Comprehensive Cancer Network
CLF	Cutaneous Lymphoma Foundation	NET	Nuova Energia Ticino
CMC	Chemistry Manufacturing and Control	NGO	Non-Governmental Organization
CN	China	NMPA	National Medical Products Administration
EAP	Early Access Program	NSAID	Non-Steroidal Anti-Inflammatory Drug
EMA	European Medicines Agency	NJ	New Jersey
ESG	Environmental, Social & Governance	NJBIA	New Jersey Business Industry Association
EU	European Union	ODD	Orphan Drug Designation
EV	Electric vehicle	PEFT	Programme for the Endorsement of Forest Certification
FDA	Food and Drug Administration (US)	PEG	Polyethylene glycol
FIT	Farma Industria Ticino	PIC	Pharmaceutical Inspection Convention
FSC	Forest Stewardship Council	PMDA	Pharmaceuticals and Medical Devices Agency (Japan)
GHG-P	Greenhouse Gas Protocol	PONV	Post-Operative Nausea and Vomiting
GMP	Good Manufacturing Practice	PRC	People's Republic of China
GRI	Global Reporting Initiative	R&D	Research & Development
GxP	Good (Anything...) Practice	RET	REarranged during Transfection
JP	Japan	RoW	Rest of the World
HAS	Helsinn Advanced Synthesis SA	SA	Società Anonima (anonymous company)
HHC	Helsinn Healthcare SA	SASB	Sustainability Accounting Standard Boards
HBP	Helsinn Birex Pharmaceuticals Ltd	SDGs	Sustainable Development Goals (United Nations)
HCPs	Healthcare Professionals	SIOG	International Society for Geriatric Oncology
HIS	Helsinn International Services Sarl	SPCC	Sharing Progress in Cancer Care
HIF	Helsinn international Fund SA	UK	United Kingdom
HPAPI	High Potency Active Pharmaceuticals Ingredient	US	United States
HPC	Helsinn Pharmaceuticals China	SCWD	Society on Sarcopenia, cachexia and disorders

